STUB1 and neoplasm: The MRD assay, with an analytical limit of detection of 0.005% tumor fraction and algorithm criteria for ctDNA status determination developed in an independent data set, utilizes 50‐200 patient‐specific variants identified using WES, with germline subtraction and exclusion of CHIP variants for detection of ctDNA.